< Back to previous page
Researcher
Chris Verslype
- Disciplines:Oncology
Affiliations
- Digestive Oncology (Division)
Member
From1 Aug 2022 → Today - Clinical Digestive Oncology (Division)
Member
From22 May 2017 → Today - Hepatology (Division)
Member
From1 Oct 2002 → 21 May 2017
Projects
1 - 10 of 14
- Impact of ccfDNA on clinical decision making in NEN patientsFrom1 Jan 2023 → TodayFunding: Foundations, funds and other with scientific goal
- Obesity-associated Hepatocellular Carcinoma at Single Cell Resolution for Risk Prediction and Novel Therapeutics - HepatoSCRIPTFrom1 Jan 2023 → TodayFunding: Foundations, funds and other with scientific goal
- [18F]AlF-NOTA-octreotide PET imaging of the somatostatin receptor in neuroendocrine tumors: comparison with [68Ga]Ga-DOTATATE and evaluation of routine clinical use.From3 Oct 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- robotiC gUided canceR nanomedicinE (CURE)From1 Oct 2021 → TodayFunding: BOF - projects
- New Strategies in Locoregional, Minimally Invasive Therapy of Liver CancerFrom1 Jul 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- The search for biomarkers in systemic treatment of advanced hepatocellular carcinoma.From1 Oct 2019 → 1 Oct 2023Funding: FWO Strategic Basic Research Grant
- Methylome analysis in circulating tumor DNA to predict baseline or aquired sorafenib resistance in hepatocellular carcinoma patientsFrom1 Jan 2019 → 31 Dec 2022Funding: Foundations, funds and other with scientific goal
- Daphnia: from ecological to biomedical microbiome model in the context of hypoxiaFrom1 Sep 2018 → 26 Jun 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
- The role of cytopathology in the management of patients with pancreatic tumours - special focus on neuroendocrine tumoursFrom15 Jun 2017 → 17 Sep 2018Funding: Own budget, for example: patrimony, inscription fees, gifts
- Pancreatic cancer: study of tumor biology and EMT with testing of corresponding drugs in a relevant pre-clinical modelFrom1 Oct 2016 → 30 Sep 2018Funding: BOF - Other initiatives
Publications
41 - 50 of 304
- Laparoscopic liver resection for colorectal liver metastases: retrospective analysis of prognostic factors and oncological outcomes in a single-center cohort(2022)
Authors: Louis Libbrecht, Chris Verslype
Pages: 2399 - 2414 - Long-term outcome of liver transplantation for unresectable liver metastases from neuroendocrine neoplasms: a Belgian retrospective multi-centre study(2022)
Authors: Jacques Pirenne, Chris Verslype
Pages: 13 - 13 - Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial(2022)
Authors: Chris Verslype
Pages: 2547 - 2554 - Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (vol 4, pg v238, 2018)(2022)
Authors: Chris Verslype
Pages: 666 - 666 - Pembrolizumab in patients with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the open- label, phase 2 KEYNOTE-224 study(2022)
Authors: Chris Verslype
Pages: S362 - S362 - Mimicry of an acute pseudocyst by a gastrointestinal duplication cyst in a 14-year-old boy(2022)
Authors: Gert De Hertogh, Chris Verslype, Wim Laleman
Pages: E271 - E272 - The European Neuroendocrine Tumour Society registry, a tool to assess the prognosis of neuroendocrine neoplasms(2022)
Authors: Chris Verslype
Pages: 80 - 90 - A Hybrid Particle-Flow CFD Modeling Approach in Truncated Hepatic Arterial Trees for Liver Radioembolization: A Patient-specific Case Study(2022)
Authors: Chris Verslype, Geert Maleux
- Development and external validation of a prediction model for overall survival after resection of distal cholangiocarcinoma(2022)
Authors: Chris Verslype
Pages: 1280 - 1288 - Early Whole-Body Diffusion-weighted MRI Helps Predict Long-term Outcome Following Peptide Receptor Radionuclide Therapy for Metastatic Neuroendocrine Tumors(2022)
Authors: Elin Pauwels, Kristof Baete, Paul Clement, Kristiaan Nackaerts, Chris Verslype, Christophe Deroose